Cost-effectiveness of aumolertinib versus osimertinib as second-line regimen for EGFR T790M-positive patients with advanced non-small cell lung cancer
Objective To evaluate the pharmacoeconomics of aumolertinib as a second-line regimen for EGFR T790M-positive patients with advanced non-small cell lung cancer(NSCLC)from the perspective of Chinese healthcare system,and to provide reference for clinical medication selection.Methods A three-state partitioned survival model was used in the cost-effectiveness analysis.Survival data were sourced from the APOLLO and AURA3 clinical trials,while parameter for cost and effectiveness were derived from published literatures.A pharmacoeconomic evaluation was performed for EGFR T790M-positive patients with advanced NSCLC treated with aumolertinib and osimertinib,respectively.The sensitivity of the results was analyzed.Results In the base-case analysis,aumolertinib improved survival benefits but increased the costs as compared with osimertinib,with an incremental cost-effectiveness ratio(ICER)of 218 926.80 Yuan per quality-adjusted life year(QALY).Univariate sensitivity analysis indicated that the costs of both aumolertinib and osimertinib greatly influenced the ICER.Probabilistic sensitivity analysis showed that the probability of aumolertinib being cost-effective increased as the willingness-to-pay(WTP)threshold rose.Conclusion From the perspective of the Chinese healthcare system,with a WTP threshold set at three times the per capita GDP of China,aumolertinib is economically viable as compared with osimertinib as second-line regimen for EGFR T790M-positive patients with advanced NSCLC.The economic advantage of aumolertinib over osimertinib increases with the WTP threshold.
NETL
NSTL
万方数据
